According to several healthcare CIOs giving testimony yesterday in the District of Columbia, hospitals are pressed for both time and money when it comes to implementing the necessary changes to their EHR systems and clinical workflows.
For eligible hospitals (EHs), the next phase of the EHR Incentive Programs (i.e., Stage 2 Meaningful Use) begins in October. According to several healthcare CIOs giving testimony yesterday in the District of Columbia, hospitals are pressed for both time and money when it comes to implementing the necessary changes to their EHR systems and clinical workflows.
The Implementation Workgroup, a subcommittee of the Health Information Technology Standards Committee (HITSC), held an all-day hearing featuring four panels, two of which dealing with the challenges facing eligible providers preparing for Stage 2 Meaningful Use.
During the third panel of the Implementation and Usability Hearing, a select panel of healthcare CIOs gave testimony in response to questions posed by the HITSC workgroup. Considering the number of mandates and initiatives hospitals are facing in the coming use, a common theme emerged among the panelists: Many hospitals lack both the time and money to keep pace with meaningful use on top of their other responsibilities.
Read the full story: http://bit.ly/13DXJNv
Source: EHR Intelligence
Gene Therapy Enhances Visual Processing for Inherited Retinal Disease
December 3rd 2024Gene therapy partially restores visual processing in the geniculostriate pathway of patients with Leber congenital amaurosis type 2 while maintaining compensatory activity in the retinotectal pathway.
Read More
New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia
December 2nd 2024Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are: −11/+11 for symptom burden, −16/+16 for physical condition/fatigue, and −16/+13 for worries/fears.
Read More
Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC
December 2nd 2024Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.
Read More